Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07217184 · ClinicalTrials.gov registry record · Phase 1

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

A Phase 1 study of Multiple Myeloma, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 1
Development phase
30
Enrollment target
19
Study locations

NCT07217184 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 30 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The trial reports 19 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07217184, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
19
Study locations

Study Summary

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with isatuximab, and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Belantamab mafodotin
  • DRUG Isatuximab

Study Locations (19)

Other

  • GSK Investigational Site - São Paulo
  • GSK Investigational Site - Villejuif
  • GSK Investigational Site - Athens
  • GSK Investigational Site - Mexico City
  • GSK Investigational Site - Oslo
  • GSK Investigational Site - Seoul
  • GSK Investigational Site - Seoul
  • GSK Investigational Site - Ulsan
  • GSK Investigational Site - Madrid
  • GSK Investigational Site - Madrid
  • GSK Investigational Site - Pozuelo de AlarcOn Madr
  • GSK Investigational Site - Falun

Georgia

  • GSK Investigational Site - Atlanta

Massachusetts

  • GSK Investigational Site - Boston

Michigan

  • GSK Investigational Site - Grand Rapids

Wisconsin

  • GSK Investigational Site - Madison

Victoria

  • GSK Investigational Site - Fitzroy

Estado de Bahia

  • GSK Investigational Site - Salvador

Ontario

  • GSK Investigational Site - Toronto

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2021-07-29
Est. Completion 2027-03-11
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07217184

The ClinicalTrials.gov registry entry for NCT07217184 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Belantamab mafodotin is the first listed.

NCT07217184 reports 19 study locations spanning 8 distinct geographic areas - top geographies include Other, Georgia, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07217184 about?

NCT07217184 is a clinical study titled "Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM". The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with isatuximab, and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub stud...

What is the current status of trial NCT07217184?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2021-07-29. Estimated completion is 2027-03-11.

What conditions does trial NCT07217184 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT07217184?

The interventions under investigation include: Belantamab mafodotin (DRUG), Isatuximab (DRUG).

Who is sponsoring clinical trial NCT07217184?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07217184 being conducted?

This trial has 19 study locations across Georgia, Massachusetts, Michigan, Wisconsin, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.